CCL2 and breast neoplasm: Yao et al. implanted osmotic pumps containing control IgG or anti-human CCL2 neutralizing antibody (R&D system, MAB279) in nude mice bearing MCF10CA1d breast tumor xenografts and analyzed CCL2 levels and tumor progression over 4 weeks.